Transaction details
Craig E. Hunsaker, Executive Vice President, People & Culture at Alphatec Holdings Inc. (NASDAQ: ATEC), sold 37,358 shares of common stock on February 3, 2026 for approximately $549,536, according to a Form 4 filing with the Securities and Exchange Commission. The sales were executed at a weighted average price of $14.71 per share, with individual trades reported in the range of $14.38 to $14.91.
The filing states the disposition was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. The plan was implemented to cover tax obligations associated with the vesting of restricted stock units.
Post-sale ownership and equity adjustments
After the February 3 transaction, Hunsaker directly holds 1,173,025 shares of Alphatec. The Form 4 also notes that 46,175 previously reported restricted stock units were forfeited because certain performance criteria were not met.
Financial snapshot and recent results
Alphatec is currently not profitable on a trailing twelve-month basis, recording earnings per share of -$1.05. Analyst expectations reflected in available research suggest the company should move to profitability this year. The company has reported robust top-line expansion, with revenue growth of 27% noted in filings and commentary.
In its preliminary release for the fourth quarter and full-year 2025, Alphatec modestly exceeded expectations. Management provided a 2026 revenue forecast of $890 million, representing 17% growth year-over-year. That forecast is below the company’s historical growth rate but is slightly above the analyst consensus figure of $886.9 million.
Market reaction and analyst positioning
Following the preliminary results and guidance, Alphatec’s share price fell sharply, declining nearly 20% after the announcement. Several brokerages issued or reiterated coverage notes: Freedom Capital Markets and Canaccord Genuity both maintained Buy ratings with $25.00 price targets. TD Cowen revised its price target downward to $20.00 from $27.00, citing valuation concerns while retaining a Buy rating. Stifel commented that Alphatec’s Q4 2025 revenue growth showed a deceleration relative to more recent quarters but remained above historical averages; Stifel attributed the slowdown to particularly strong earlier-quarter performance rather than to a material downturn.
Alphatec is preparing to present at the upcoming JPM healthcare conference, according to the company’s investor communications.
Where to find further analysis
Comprehensive analyst research and equity reports are available through the company’s research publications and extended coverage platforms for investors seeking additional detail on Alphatec and a broad set of US-listed equities.